Trade

with

Cempra Inc
(NASDAQ: CEMP)
AdChoices
12.22
-0.03
-0.24%
After Hours :
12.22
+0.00
+0.01%

Open

12.45

Previous Close

12.25

Volume (Avg)

297.64k (221.04k)

Day's Range

12.01-12.59

52Wk Range

8.10-15.39

Market Cap.

407.23M

Dividend Rate ( Yield )

-

Beta

1.18

Shares Outstanding

33.24M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 7.81M

    • Net Income

    • -45.03M

    • Market Cap.

    • 407.23M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -776.61

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.18

    • Forward P/E

    • -6.12

    • Price/Sales

    • 49.50

    • Price/Book Value

    • 10.44

    • Price/Cash flow

    • -6.89

      • EBITDA

      • -42.86M

      • Return on Capital %

      • -65.10

      • Return on Equity %

      • -92.68

      • Return on Assets %

      • -65.10

      • Book Value/Share

      • 1.17

      • Shares Outstanding

      • 33.24M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 11.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.94

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -58.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -776.61

            • 39.38

            • Net Profit Margin

            • -776.61

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.45

              • 0.76

              • Current Ratio

              • 6.55

              • 2.92

              • Quick Ratio

              • 6.28

              • 2.35

              • Interest Coverage

              • -24.00

              • 38.02

              • Leverage Ratio

              • 1.88

              • 2.21

              • Book Value/Share

              • 1.17

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -6.04

                • 188.68

                • P/E Ratio 5-Year High

                • -8.01

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.74

                • 124.82

                • Price/Sales Ratio

                • 46.95

                • 8.72

                • Price/Book Value

                • 9.88

                • 7.95

                • Price/Cash Flow Ratio

                • -6.89

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -92.68

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -65.10

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -72.04

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.08

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -42.92M
                  Operating Margin
                  -549.35
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -6.89
                  Ownership

                  Institutional Ownership

                  95.26%

                  Top 10 Institutions

                  66.98%

                  Mutual Fund Ownership

                  23.24%

                  Float

                  68.85%

                  5% / Insider Ownership

                  2.93%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wasatch Small Cap Growth Fund

                  •  

                    1,752,428

                  • 12.30

                  • 5.27

                  • iShares Nasdaq Biotechnology

                  •  

                    444,311

                  • 3.08

                  • 1.49

                  • iShares Russell 2000 (AU)

                  •  

                    363,682

                  • 1.39

                  • 1.22

                  • AXA Framlington Biotech

                  •  

                    360,863

                  • 0.00

                  • 1.07

                  • Vanguard Total Stock Mkt Idx

                  •  

                    326,839

                  • 0.00

                  • 0.98

                  • Grandeur Peak Global Opportunities Fund

                  •  

                    319,200

                  • 30.71

                  • 0.96

                  • Putnam Global Health Care Fund

                  •  

                    271,257

                  • 0.00

                  • 0.82

                  • CI Cambridge American Equity Corporate

                  •  

                    250,000

                  • 0.00

                  • 0.75

                  • Carnegie Global Healthcare

                  •  

                    250,000

                  • 0.00

                  • 0.74

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Quaker BioVentures Capital II, LLC

                  •  

                    3,527,154

                  • +8.12%

                  • 10.62

                  • Wasatch Advisors Inc.

                  •  

                    3,449,078

                  • +11.75%

                  • 10.38

                  • Intersouth Partners

                  •  

                    3,316,286

                  • 0.00%

                  • 9.99

                  • Aisling Capital Partners LLC

                  •  

                    3,293,060

                  • 0.00%

                  • 9.92

                  • Pyramis Global Advisors, LLC

                  •  

                    1,496,722

                  • +2.60%

                  • 4.50

                  • Ontario Teachers Pension Plan Board

                  •  

                    1,209,506

                  • 0.00%

                  • 3.64

                  • BlackRock Fund Advisors

                  •  

                    960,455

                  • -0.18%

                  • 2.89

                  • Broadfin Capital, LLC

                  •  

                    955,147

                  • 0.00%

                  • 2.87

                  • PointState Capital LP

                  •  

                    750,000

                  • 0.00%

                  • 2.26

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  -

                  Cempra Inc is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. The Company is a clinical-stage pharmaceutical company which is engaged in the d...moreevelopment of differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s main product, solithromycin (CEM-101), is in Phase 3 clinical trials. The Company is developing solithromycin in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP. Solithromycin is a potent new fourth generation macrolide an...mored the first fluoroketolide in clinical development. The Company is also completed a Phase 2 study of solithromycin in uncomplicated gonorrhea. Its second program is Taksta, which the Company is developing in the U.S. as a long term oral treatment for prosthetic joint infections caused by staphylococci, including S. aureus and MRSA. The Company is conducting a Phase 2 trial for Taksta in patients with prosthetic joint infections and have submitted a proposal for a Phase 3 trial for Tasksta as a treatment for PJI. The Company has licensed solithromycin to Toyama Chemical Co., Ltd. for development and commercialization in Japan while retaining the rights to the rest of the world. The Company is developing Taksta in the U.S. as a long term oral treatment of prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus, or MRSA.lessless

                  Key People

                  Dr. Prabhavathi Fernandes, PhD

                  CEO/Director/Founder/President

                  Dr. Garheng Kong, PhD

                  Chairman of the Board/Director

                  Mr. Mark W. Hahn

                  CFO/Executive VP

                  P. Sherrill Neff

                  Director

                  Dr. Richard S. Kent,M.D.

                  Director

                  • Cempra Inc

                  • 6320 Quadrangle Drive

                  • Chapel Hill, NC 27517

                  • USA.Map

                  • Phone: +1 919 313-6601

                  • Fax: -

                  • cempra.com

                  Incorporated

                  2005

                  Employees

                  38

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: